Rafferty Asset Management LLC purchased a new position in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 68,863 shares of the company’s stock, valued at approximately $92,000.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in TXMD. Morgan Stanley lifted its position in TherapeuticsMD by 6,296.3% in the fourth quarter. Morgan Stanley now owns 9,278,408 shares of the company’s stock valued at $11,227,000 after purchasing an additional 9,133,350 shares during the period. BlackRock Inc. lifted its position in TherapeuticsMD by 28.8% in the first quarter. BlackRock Inc. now owns 27,597,421 shares of the company’s stock valued at $36,981,000 after purchasing an additional 6,178,148 shares during the period. Laurion Capital Management LP acquired a new stake in TherapeuticsMD in the fourth quarter valued at about $4,006,000. Handelsbanken Fonder AB lifted its position in TherapeuticsMD by 30.0% in the fourth quarter. Handelsbanken Fonder AB now owns 3,250,000 shares of the company’s stock valued at $3,916,000 after purchasing an additional 750,000 shares during the period. Finally, Virtu Financial LLC acquired a new stake in TherapeuticsMD in the fourth quarter valued at about $687,000. 44.31% of the stock is currently owned by hedge funds and other institutional investors.
Shares of TXMD stock opened at $1.34 on Friday. TherapeuticsMD, Inc. has a fifty-two week low of $1.00 and a fifty-two week high of $2.75. The stock has a market capitalization of $526.87 million, a PE ratio of -2.35 and a beta of 1.93. The firm has a fifty day moving average price of $1.21.
Separately, Zacks Investment Research upgraded shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a research report on Thursday, May 13th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $4.11.
In related news, EVP Edward Borkowski sold 44,252 shares of the stock in a transaction on Tuesday, May 11th. The stock was sold at an average price of $1.04, for a total transaction of $46,022.08. Following the sale, the executive vice president now owns 103,500 shares of the company’s stock, valued at $107,640. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Robert G. Finizio sold 67,697 shares of the stock in a transaction on Tuesday, May 11th. The shares were sold at an average price of $1.04, for a total value of $70,404.88. Following the sale, the chief executive officer now directly owns 18,059,334 shares in the company, valued at approximately $18,781,707.36. The disclosure for this sale can be found here. In the last 90 days, insiders sold 138,383 shares of company stock valued at $143,918. Company insiders own 8.80% of the company’s stock.
TherapeuticsMD, Inc operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17Ã-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system.
Featured Article: Blue-Chip Stocks
Want to see what other hedge funds are holding TXMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TherapeuticsMD, Inc. (NASDAQ:TXMD).
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.